Celltrion’s Bone Disease Biosimilar Wins FDA Approval in the U.S.
Celltrion announced on the 4th that its bone disease treatment biosimilars Stoboclo and Osenvelt—biosimilars of Prolia and Xgeva…
prolia
2 개의 기사가 있습니다.
Celltrion Secures First Approval for Prolia Biosimilar in Korea
Celltrion has received its first approval for a biosimilar of Prolia (denosumab), a treatment for osteoporosis. On the…